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Cetuximab-conjugated gold nanoparticles are known to target cancer cells, but display toxicity towards normal kidney,
liver and endothelial cells in vitro. In this study, we investigated their pharmacokinetics, biodistribution and toxicity after
intravenous administration in healthy mice. Our data showed that these nanoparticles were rapidly cleared from the blood
and accumulated mainly in the liver and spleen with long-term retention. Acute liver injury, inflammatory activity and
vascular damage were transient and negligible, as confirmed by the liver functionality tests and serum marker analysis.
There was no sign of altered liver, kidney, lung and spleen morphology up to 4 weeks post-injection. After 6 months,
kidney casts and splenic apoptosis appeared to be more prevalent than in the controls. Furthermore, occasional immune
cell infiltration was observed in the lungs. Therefore, we recommend additional in vivo studies, in order to investigate the
long-term toxicity and elimination of gold nanoparticles after multiple dosing in their preclinical validation as new targeted
anti-cancer therapies.
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INTRODUCTION
Over the last few decades, applications of gold nanopar-
ticles (AuNPs) in nanomedicine have developed exten-
sively due to their unique physicochemical properties.
Furthermore, the possibility of modifying the surface of
AuNPs with targeting agents strengthens their potential
use in the diagnosis, monitoring and treatment of can-
cer [1, 2]. Our previous studies have shown that AuNPs,
coated with poly-allylamine and conjugated to Cetux-
imab (AuNPs-PAA-Ctxb), successfully targeted cancer
cells that were overexpressing the epidermal growth fac-
tor receptor (EGFR), both in vitro and in vivo [3, 4].
Furthermore, AuNPs-PAA-Ctxb selectively radiosensitized
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EGFR-overexpressing cancer cells, thus increasing the
efficacy of 25 keV/m proton therapy (3.0 Gy) by
22% [5, 6]. Several studies indicate that the physical
interaction between AuNPs and radiation, leading to low-
energy electron emission, is unlikely to be the only mech-
anism responsible for the radiosensitizing property of
AuNPs [7, 8]. In fact, it has been demonstrated that
AuNPs also exert a direct biological effect on the cells.
More specifically, AuNPs caused mitochondrial dysfunc-
tion, inhibition of the thioredoxin antioxidant defense sys-
tem and oxidative stress in various cancer cells, which may
predispose these cells to the damaging effects of ionizing
radiation [9–12]. Moreover, we recently observed the same
biological effects in non-cancerous, human kidney, liver
and microvascular endothelial cells exposed to AuNPs-
PAA-Ctxb in vitro. This indicates a general AuNP cyto-
toxicity mechanism, which is not cancer cell specific [13].
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When administered in vivo, the reticuloendothelial sys-
tem (RES) is able to identify AuNPs as foreign sub-
stances that need to be sequestered and eliminated, while
the renal system rapidly excretes AuNPs that are smaller
than 5.5 nm. Therefore, the kidneys and RES organs, such
as the liver, spleen and lungs can encounter a significant
proportion of the administered AuNPs [14]. Therefore,
although AuNPs hold promise to enhance the effective-
ness of cancer radiotherapy, off-target accumulation and
the cytotoxicity effects of AuNPs observed in normal cells
warrant further investigation with respect to their potential
toxicity and immunogenicity in vivo.
Several studies have reported on the toxicity of AuNPs
in vivo, but with conflicting conclusions. Some reports
have described how AuNPs can cause acute inflammation,
changes in white blood cell levels, changes in liver and
kidney functional parameters, emphysema of the lungs and
damage to the liver, spleen and kidneys [15–20]. This is
in contrast to other studies, which could not detect defi-
nite signs of in vivo toxicity [21–24]. This apparent dis-
crepancy stems from differences in study set-up, with the
administration route and dosage playing a pivotal role. In
addition, the size, coating, surface charge and shape of
the AuNPs also influenced the biodistribution and toxicity
outcome [21, 25, 26].
In this study, we investigated the pharmacokinetics,
biodistribution and potential toxicity of our unique, in-
house produced AuNPs-PAA-Ctxb in healthy BL6/57
male mice. As previously described, AuNPs-PAA-Ctxb are
spherical and negatively charged (−7.04±0.22 mV in cell
culture medium, including 10% fetal bovine serum). These
nanoparticles, including the gold core and coating, have a
diameter of 4–5 nm, but the size increases to 26 nm if the
antibody-functionalization is taken into account [13]. At
specific time points after intravenous (IV) injection (5 min,
15 min, 30 min, 1 h, 6 h, 24 h, 72 h, 1 week, 4 weeks and
6 months), mice were sacrificed in order to collect their
blood, lungs, kidneys, liver and spleen. The biodistribu-
tion of the AuNPs-PAA-Ctxb in these tissues was assessed
using inductively coupled plasma mass spectrometry (ICP-
MS). In addition, the in vivo toxicity was evaluated by
monitoring the tissue morphology and functional parame-
ters of the liver. Finally, we screened for certain cytokines
that are involved in an immune response or specifically
linked to cardiovascular damage because of the previously
observed sensitivity of human microvascular endothelial
cells to AuNPs-PAA-Ctxb [13].
EXPERIMENTAL DETAILS
Chemicals
Cetuximab (Erbitux® 5 mg/ml) was kindly provided by
the Sint-Dimpna Hospital (Geel, Belgium). Arabic gum
(AG), the aspartate aminotransferase (AST) activity assay
kit (MAK055), the alanine transaminase (ALT) activ-
ity assay kit (MAK052), the alkaline phosphatase (ALP)
diethanolamine activity kit (AP0100), the gamma glu-
tamyl transferase (GGT) activity colorimetric assay kit
(MAK089), hematoxylin, eosin and formalin were pur-
chased from Sigma–Aldrich (Diegem, Belgium). Paraplast
Plus was obtained from Leica Microsystems (Diegem,
Belgium) and Nembutal was purchased from Ceva Santé
Animale N.V. (Brussels, Belgium). Nitric acid (HNO3),
hydrochloric acid (HCl), hydrogen peroxide (H2O2) and
hydrofluoric acid (HF) were of trace metal grade and pur-
chased from Fisher Scientific (Merelbeke, Belgium). The
external calibration and internal standards were prepared
using SPEX Certiprep certified standard solutions (Boom
B.V., Meppel, The Netherlands).
Gold Nanoparticles and Antibody Conjugation
AuNPs-PAA were produced and conjugated to Cetuximab
as previously described [5, 13, 27]. Aliquots of 900 g of
gold were freeze-dried containing 3% AG. Before injec-
tion, the AuNPs-PAA-Ctxb were re-suspended in 1 ml of
sterile 0.9% NaCl using pulsed sonication (50 W, 30 kHz,
20% amplitude, 0.5 sec pulses).
Animal Study
Healthy adult (8–10 weeks) male C57/Bl6 mice were
housed under standard laboratory conditions with a
12:12 hour light/dark cycle and 4–5 animals per cage.
Food and water were available ad libitum. All ani-
mal experiments were approved by the Ethical Commit-
tee Animal Studies of Medanex Clinic and conducted
in compliance with the European Communities Council
Directive of September 22, 2010. Ten groups of 5–6 ani-
mals received a single, non-lethal, IV injection of 100 l
of AuNPs-PAA-Ctxb suspension (90 g of gold). The ani-
mals were anesthetized by intraperitoneal administration
of 100 l Nembutal and euthanized by cardiac puncture,
which enabled the collection of blood samples at 5 min,
15 min, 30 min, 1 h, 6 h, 24 h, 72 h and 1 week post-
injection in EDTA-coated tubes. In addition, the liver, the
spleen, the kidneys and the lungs were collected at 6 h,
24 h, 72 h, 1 week, 4 weeks and 6 months post-injection.
Control mice received 100 l of 0.9% NaCl or 3% AG and
were euthanized at 6 h, 24 h or 6 months post-injection, as
described above. All the animals were randomly assigned
to each time point group.
Inductively Coupled Plasma Mass Spectrometry
The liver, spleen, right kidney and right lung intended for
ICP-MS analysis were weighed and homogenized using
the TissueLyser II (Qiagen, Antwerp, Belgium). Next, 25–
75 mg of blood or homogenized tissue was digested in
3 ml concentrated HNO3 and 1 ml of H2O2 for 4 h at
110 C on a hotplate. The samples were evaporated to
incipient dryness, followed by digestion with 4 ml of aqua
regia overnight at 110 C. After evaporation, the dried
samples were dissolved in 5–10 ml of 5% (v/v) aqua
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regia. Prior to a 2 h UV digestion treatment in a 705 UV
digester (Metrohm, Zwijndrecht, Belgium), the samples
were spiked with 100 L of 30% H2O2 to initiate radical
formation. Finally, 0.05% HF was added to all samples
in order to reduce Au memory effects in the ICP-MS
introduction system. The gold concentration in the sam-
ples was quantified using an XSeriesII quadrupole ICP-MS
instrument (ThermoFisher Scientific, Bremen, Germany)
using external calibration standards containing 0.5, 1, 2
and 5 ng/mL of gold. Data was collected from 20 ms dwell
time per isotope, 200 sweeps per reading, and 5 read-
ings per sample. A rinsing time of 150 s with a solution
containing 5% aqua regia and 0.05% HF was included
between each sample. The elements Re, Ir, Tl were used
as internal standards. The results are expressed as g of
gold per gram of tissue.
Histological Examination
The right medial lobe of the liver, left kidney, left lung
and 1/4th of the spleen intended for histological exami-
nation were fixed in 10% formalin for 24 h, after which
the samples were dehydrated and embedded in paraffin.
Seven m sections were then prepared and stained with
hematoxylin and eosin (H&E) according to a standard pro-
tocol. Bright-field images were obtained using a Nikon
Ti-Eclipse microscope.
Liver Enzyme Activity Measurement and
Luminex Analysis
Blood samples intended for liver enzyme activity mea-
surements and luminex analysis were collected at 6 h
and 24 h after injection in serum collection tubes. The
blood samples were allowed to clot for 30 minutes at
room temperature, after which serum was isolated by cen-
trifugation at 10,000 g for 5 min, aliquoted and stored
in Eppendorf tubes at −20 C until analysis. In order
to evaluate liver toxicity, the enzyme activity of AST,
ALT, GGT and ALP in serum samples was measured. For
this purpose, specific assay kits were used according to
the manufacturer’s instructions. Samples were measured
in duplicate and results were expressed as milliunits/ml
(mU/ml). In order to evaluate immunotoxicity and cardio-
vascular damage, serum levels of CCL2, CCL5, CXCL10,
EGF, FGF2, GDF-15, ICAM-1, IFN, IL-1, IL-2, IL-4,
IL-6, IL-10, PCK9, P-Selectin, TNF, uPAR were ana-
lyzed using a multiplex magnetic bead array (R&D sys-
tems). The luminex assay was performed according to
manufacturer’s instructions. Samples were measured in
duplicate using a Luminex 200 and analyzed with xPO-
NENT 3.1 (Luminex Corporation).
Statistical Analysis
Results were reported as a mean± standard error (SE).
One-way ANOVA was used to test for significant dif-
ferences between the different treated groups and control
groups, followed by a Holm-Sidak post-hoc test in order to
correct for multiple comparisons. The statistical analyses
were performed using Prism 7.02 software. The level
of statistical significance is indicated by the number of




The AuNPs-PAA-Ctxb blood concentration-time curve
was fitted by a three-phase exponential decay function,
using Origin 2017 (Fig. 1). The pharmacokinetic parame-
ters are summarized in Table I. The maximum Au concen-
tration (Cmax) in the blood was reached immediately after
IV injection (Tmax). Our data showed that AuNPs-PAA-
Ctxb were rapidly eliminated from the blood circulation,
leading to a rapid fall in the initial gold concentration.
This explains the short initial half-life (T1/2) of 2.3 min-
utes (i.e., the time required for the Au concentration in
the blood to decrease by 50% of its initial value at Tmax
(5 min post-injection)). This fast clearance was followed
by a more gradual decline in Au concentration, which was
associated with longer half-lives (T1/2 and T1/2). After
6 h, 97% of the initial Au concentration was removed from
the blood. Since the gold content in the blood was detected
until 1 week after injection, an area under the curve (AUC)
of 22.3 g ·h ·ml−1 and an average blood clearance (Cbl)
of 4.0 ml ·h−1 were calculated.
Tissue Distribution
In terms of pharmacokinetics, we observed a rapid clear-
ance of the AuNPs-PAA-Ctxb from the blood to the
tissues. Sequestration of AuNPs by the RES organs is

















Figure 1. Blood pharmacokinetic profile of AuNPs-PAA-Ctxb.
Mean gold concentration (g/ml) in the blood at 5 min, 15 min,
30 min, 1 h, 6 h, 24 h, 72 h and 1 week after a single IV admin-
istration (90 g gold). Error bars represent SE (n = 5–6).
Abbreviations: AuNPs-PAA-Ctxb: Gold nanoparticles coated
with poly-allylamine and conjugated to Cetuximab; IV: Intra-
venous; SE: Standard error.
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Table I. Pharmacokinetic parameters based on the AuNPs-
PAA-Ctxb blood concentration-time curve.
Parameter AuNPs-PAA-Ctxb∗
T †max 5 min







T ¶1/2 15.6 h
AUC#0h →1 week 22.3 g ·h ·ml−1
C∗∗bl 4.0 ml ·h−1
Notes: ∗Gold nanoparticles coated with poly-allylamine and conjugated to
Cetuximab; †time point of maximum observed concentration, ‡maximum
observed concentration, §short half-life, medium half-life, ¶long half-life,
#AUC: Area under the curve, ∗∗average blood clearance over 1 week.
a well-known phenomenon after IV administration [28].
Furthermore, the kidneys can eliminate AuNPs that are
smaller than 5.5 nm [14]. Considering the above, we
assessed the concentration of AuNPs-PAA-Ctxb using
ICP-MS in several RES organs (i.e., liver, spleen, lungs)
and the kidneys. Since 97% of the AuNPs-PAA-Ctxb
were cleared from the blood circulation after 6 h, AuNPs-
PAA-Ctxb distribution was assessed at 6 h, and further
monitored at 24 h, 72 h, 1 week, 4 weeks and 6 months
post-administration. Figure 2 indicates that AuNPs-PAA-
Ctxb accumulated primarily in the liver and the spleen.
The gold concentration (g gold/g tissue) was highest
in the spleen, followed by the liver, lung and kidney.
However, considering the different sizes of the organs,
the percentage of injected dose (%ID) was higher in the
Figure 2. Biodistribution of AuNPs-PAA-Ctxb. Mean gold
concentration (g/g) in liver, spleen, kidney and lung at 6 h,
24 h, 72 h, 1 week, 4 weeks and 6 months after a single IV
injection (90 g gold). Error bars represent SE (n = 5–6). The
statistical difference compared to 6 h post-injection was cal-
culated by a One-way ANOVA and a Holm-Sidak post-hoc test
(∗p < 005, ∗∗p < 001, ∗∗∗p < 0001 ∗∗∗∗p < 00001).
Abbreviations: AuNPs-PAA-Ctxb: Gold nanoparticles coated
with poly-allylamine and conjugated to Cetuximab; IV: Intra-
venous; SE: Standard error.
liver than in the spleen (Table II). In the liver, the gold
concentration significantly increased over time, reaching
a maximum value after 72 h (67.24 g/g). A similar
increasing trend in gold concentration was observed in the
spleen (maximum after 72 h: 96.34 g/g). In both liver
and spleen, the increase in gold concentration was fol-
lowed by a significant decline after 6 months (32.11 g/g
liver and 41.76 g/g spleen). In the lung, the maximum
gold concentration was observed after 6 h (7.014 g/g).
This concentration then significantly decreased after 24 h
(2.749 g/g). Finally, the lowest gold concentrations were
observed in the kidney (maximum after 24 h: 0.765 g/g),
which significantly decreased after 1 week (0.446 g/g).
Evaluation of Liver Toxicity
Our biodistribution results showed that a major propor-
tion of the injected AuNPs-PAA-Ctxb accumulated in the
liver. Therefore, we evaluated the effect of AuNPs-PAA-
Ctxb on the liver by measuring the activity of serum ALT,
ALP, AST and GGT. Since 97% of the AuNPs-PAA-Ctxb
were distributed to the tissues after 6 h, we assessed acute
responses at 6 h and 24 h post-injection. AuNPs-PAA-
Ctxb injection led to a small, but significant increase in
ALT activity after 6 h, as compared to the arabic gum
control group (Fig. 3(A)). Similarly, AST activity signif-
icantly increased 6 h after AuNPs-PAA-Ctxb injection,
compared to the 0.9% NaCl control group (Fig. 3(B)).
In both cases, the increase was transient and undetectable
after 24 h. In terms of ALP activity, no significant dif-
ferences were observed (Fig. 3(C)). Finally, GGT activity
was undetectable in all serum samples.
Evaluation of Immunotoxicity and
Vascular Damage
The liver and spleen are important lymphoid organs with
resident immune cells that can mount a rapid immune
response when they encounter antigenic particles. Fur-
thermore, in our previous research, we demonstrated that
microvascular endothelial cells were the most sensitive
cells to AuNPs-PAA-Ctxb when compared to human kid-
ney and liver cells [13]. Therefore, we measured the serum
levels of several markers that are related to inflamma-
tory activity and vascular damage (RANTES, IFN, IL-
1, IL-2, IL-4, IL-6, IL-10, TNF, GDF-15, ICAM-1,
CCL2, CXCL-10, P-selectin, PCSK9, uPAR). Since the
RES organs rapidly sequestrate the injected AuNPs-PAA-
Ctxb, we assessed responses 6 h and 24 h post-injection.
No significant increases in serum levels of TNF, CCL2,
IL-1, IL-2, IL-4, IL-6, IL-10, IFN, CXCL-10, PCSK9
and uPAR were observed after administration of AuNPs-
PAA-Ctxb (data not shown). On the contrary, serum levels
of GDF-15 and P-selectin significantly increased 6 h after
AuNPs-PAA-Ctxb injection, as compared to both the 0.9%
NaCl and AG control groups. This response was tran-
sient and no longer detectable after 24 h (Figs. 4(A–B)).
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Table II. Biodistribution of AuNPs-PAA-Ctxb†. Gold concentration in liver, spleen, lung and kidney at 6 h, 24 h, 72 h, 1 week,
4 weeks and 6 months after a single IV‡ injection (90 g gold) (n = 5–6). Results are expressed as the mean %ID§ ±SE. The
statistical difference compared to 6 h post-injection was calculated by a One-way ANOVA and a Holm-Sidak post-hoc test (∗p <
005, ∗∗p < 001, ∗∗∗∗p < 00001).
Theoretically calculated percentage of injected dose (%ID§) (mean±SE)
Liver Spleen Lung Kidney
6 h 50±3 4.5±0.3 0.72±0.07 0.124±0.005
24 h 48±5 5.5±0.4 0.30±0.08∗∗∗∗ 0.14±0.02
72 h 62±2∗ 5.5±0.7 0.36±0.06∗∗∗∗ 0.106±0.009
1 week 52±1 3.9±0.3 0.15±0.02∗∗∗∗ 0.08±0.01∗
4 weeks 47±2 5.5±0.5 0.069±0.007∗∗∗∗ 0.061±0.005∗∗
6 months 40±3 (p = 0058) 2.4±0.2∗∗ 0.045±0.008∗∗∗∗ 0.033±0.002∗∗∗∗
Notes: †Gold nanoparticles coated with poly-allylamine and conjugated to Cetuximab, ‡Intravenous, §Percentage of the injected dose, Standard error.
In addition, ICAM-1 levels significantly increased 6 h
after AuNPs-PAA-Ctxb injection, as compared to the 0.9%
NaCl control group, and remained significantly elevated
after 24 h, as compared to both the 0.9% NaCl and AG
control groups. It should be noted that a near-significant
increase in the ICAM-1 level was also observed 6 h after
AG administration, compared to the 0.9% NaCl control
A B
C
Figure 3. Liver functionality tests. Liver enzyme activity of
(A) ALT, (B) AST and (C) ALP in mouse serum at 6 h and 24 h
after a single IV injection of AuNPs-PAA-Ctxb (90 g Au), 0.9%
NaCl or AG. Graphs show individual data points and the mean
activity (mU/ml) represented by columns. Error bars represent
SE (n = 5–6). The statistical difference between the treated
groups and the 0.9% NaCl control group or the 3% AG control
group was calculated by a One-way ANOVA and a Holm-Sidak
post-hoc test (∗p < 005).
Abbreviations: AG: Arabic gum; ALP: Alkaline phosphatase;
ALT: The alanine transaminase; AST: Aspartate aminotrans-
ferase; AuNPs-PAA-Ctxb: Gold nanoparticles coated with poly-
allylamine and conjugated to Cetuximab; IV: Intravenous; SE:
Standard error.
group (p = 0051) (Fig. 4(C)), which was not maintained
after 24 h. Finally, the serum level of RANTES signifi-
cantly increased 6 h after AG administration compared to
the 0.9% NaCl control group, but was no longer detected
after 24 h (Fig. 4(D)).
A B
C D
Figure 4. Markers related to inflammatory activity and vas-
cular damage. Serum levels of (A) GDF-15, (B) P-selectin,
(C) ICAM-1 and (D) RANTES in mouse serum at 6 h and 24 h
after a single IV injection of AuNPs-PAA-Ctxb (90 g Au), 0.9%
NaCl or AG. Graphs show individual data points and the mean
concentration (pg or ng/ml) represented by columns. Error
bars represent SE (n = 5–6). The statistical difference between
the treated groups and the 0.9% NaCl control group or the 3%
AG control group was calculated by a One-way ANOVA and a
Holm-Sidak post-hoc test (∗p < 005, ∗∗p < 001, ∗∗∗p < 0001).
Abbreviations: AG: Arabic gum; AuNPs-PAA-Ctxb: Gold
nanoparticles coated with poly-allylamine and conjugated to
Cetuximab; IV: Intravenous; SE: Standard error.
J. Biomed. Nanotechnol. 16, 985–996, 2020 989
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Figure 5. Histological examination. Mouse liver, kidney, spleen and lung at 1 week, 4 weeks and 6 months after a single IV
administration of AuNPs-PAA-Ctxb (90 g Au), compared to the age-related control group, which did not receive AuNPs-PAA-
Ctxb. Sections were stained with hematoxylin and eosin. Red arrows indicate immune cell infiltration in the lung, apoptotic cells
in the spleen and cast in the collecting tubules of the kidney.
Abbreviations: AuNPs-PAA-Ctxb: Gold nanoparticles coated with poly-allylamine and conjugated to Cetuximab; IV: Intravenous.
Histological Examination
Our biodistribution studies showed that a major pro-
portion of the AuNPs-PAA-Ctxb remained in the liver
and spleen 6 months post-injection. Therefore, potential
morphological effects of AuNPs-PAA-Ctxb in the organs
due to long-term exposure should be considered. Hema-
toxylin and eosin staining demonstrated normal morphol-
ogy of the liver (hepatocytes), spleen, kidney (glomeruli
and tubules) and lungs (alveoli) 1 week and 4 weeks
post-injection (Fig. 5). After 6 months, we observed a
modest increase in the number of casts in the collecting
tubules of the kidneys (5 out of 6 mice). Furthermore,
apoptotic lesions in B-cell rich areas (germinal centers)
in the white pulp of the spleen were more noticeable
than in the control group (5 out of 6 animals). Finally,
some immune cell infiltrations were found in the lungs
(4 out of 6 animals). Although the liver accumulated a
significant proportion of the injected AuNPs-PAA-Ctxb,
no major morphological changes were observed after
6 months.
DISCUSSION
This study focused on the pharmacokinetics, biodistribu-
tion and toxicity of our unique in-house produced AuNPs-
PAA-Ctxb. The dose was fixed at a single IV injection
of 90 g of gold (7.1× 1013 AuNPs-PAA-Ctxb). Based
on a previous in vitro study, in theory, this dose would
be sufficient to radiosensitize a small tumor of 11 cm3
(1.1×109 cells) when (1) the dose is extrapolated to a per-
son weighing 60 kg and (2) taking into account that 0.7%
of the injected dose would reach the tumor [3–5, 14, 29].
In addition, this dose corresponds to the standard dose
range used in most studies, which allows us to compare
our results with various in vivo studies [26]. The pharma-
cokinetic data indicated that the AuNPs-PAA-Ctxb were
promptly eliminated from the blood stream with a short
half-life of 2.3 minutes. This was followed by a predomi-
nant accumulation in the liver and spleen, and only a minor
uptake in the kidneys and lungs. This observation is similar
to the results of a recent study investigating laser-ablated,
dextran-coated AuNPs, which had a diameter of 21 nm
990 J. Biomed. Nanotechnol. 16, 985–996, 2020
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and were negatively charged. The authors demonstrated an
initial blood half-life of 4.2 minutes and identified the liver
and spleen as preferential sites for gold accumulation [30].
The pharmacokinetic results and biodistribution are partly
related to the nanoparticle zeta potential and administration
mode. Intravenous administration of nanoparticles is typi-
cally characterized by the fast adsorption of proteins to the
nanoparticle surface, creating a biological identity that is
presented to the cells. Charged AuNPs have been shown
to adsorb more and a wider variety of proteins than neu-
tral AuNPs. The formation of this protein corona strongly
affects the AuNP biodistribution and biological impacts.
For instance, adsorption of opsonins, such as complement
factors, fibrinogen and IgG antibodies promotes the recog-
nition of nanoparticles by the RES [31]. Since our AuNPs-
PAA-Ctxb are negatively charged (−7.04 ± 0.22 mV in
cell culture medium including 10% fetal bovine serum),
opsonization is likely to occur, leading to the subsequent
uptake by phagocytic cells that are in direct contact with
the blood and present in the liver and spleen. Neverthe-
less, IV delivery is a realistic exposure scenario for AuNPs
intended to be used in nanomedicine because it resists
proteolytic degradation, achieves maximum bioavailability
of the drug and allows fast onset of action [32]. Other
administration routes investigated in literature are oral
and intraperitoneal administration. Oral administration of
AuNPs is usually associated with low systemic absorption
and high gastro-intestinal elimination [33–36], whereas
intraperitoneal administration is followed by retention in
the peritoneal cavity, delayed and reduced accumulation
in the liver and spleen, and uptake in the pancreas, lungs,
lymph nodes and intestine [37–40]. Subcutaneous adminis-
tration of AuNPs has been used to visualize sentinel lymph
nodes [41].
The rapid sequestration by the RES after IV administra-
tion could potentially be delayed by modifying the surface
of AuNPs with nonionic, sterically stabilizing hydrophilic
polymers, such as polyethylene glycol (PEG). This would
neutralize the surface charges of AuNPs, shield them from
opsonization, and therefore prolong their blood circulation
half-life [15, 28, 42–50]. Furthermore, predominant accu-
mulation in the liver and spleen increases as the particle
size increases, whereas small AuNPs (1.4–10 nm) have
a wider organ distribution profile, with particles detected
in the brain, heart, uterus, testis, thymus, kidneys and
lungs [28, 51–53]. It is possible that the size of our
AuNPs-PAA-Ctxb (26 nm), together with a negative sur-
face charge, favors their uptake by the liver and spleen
after IV injection.
Interestingly, although 97% of the injected AuNPs-
PAA-Ctxb were cleared from the blood after 6 h, an
increasing trend in gold concentration was observed in
the liver and spleen for up to 72 h post-injection. Com-
parable results were obtained with PEGylated AuNPs of
different sizes (6.2 nm–61.2 nm) or with different shapes
(rods and triangles) reaching maximum gold concentra-
tions in the liver and spleen between 24 h and 6 days
post-injection [54, 55]. This increase could potentially be
attributed to a gradual redistribution of AuNPs-PAA-Ctxb
from other tissues to the liver and spleen [22]. Further-
more, with a diameter of approximately 26 nm and a nega-
tive surface charge, AuNPs-PAA-Ctxb are less likely to be
efficiently excreted by the negatively charged glomeruli,
thus allowing redistribution to occur [25]. This is consis-
tent with our biodistribution data illustrating the lowest
amount of gold in the kidneys. In contrast to the liver and
spleen, the gold concentration in the lungs and kidneys did
not initially increase, but instead progressively decreased
after 24 h and 1 week, respectively.
After sequestration in the liver and spleen, AuNPs-
PAA-Ctxb showed a long-term retention, with their con-
centration significantly decreasing only after 6 months.
This indicates a slow elimination process, which has also
been reported by several other long-term biodistribution
studies [21, 25, 55–57]. In addition, it was reported that
negatively charged particles were retained for slightly
longer in the liver and spleen, and were eliminated more
slowly compared to positively or neutrally charged par-
ticles [25, 51]. The phagocytic cells in the RES system
are responsible for recognizing and clearing AuNPs after
IV administration [28]. Sadauskas et al. investigated what
happens to negatively charged 40 nm AuNPs in the liver
and revealed that they were clustered inside endosome-
like vesicles in long-living Kupffer cells, over a period
of 6 months, and that damaged cells were cleared by
new or nearby Kupffer cells [56]. The presence of PEGy-
lated AuNPs in intracellular vesicles was also confirmed
in splenic macrophages [15, 55]. In addition, a recent
study demonstrated that the depletion of Kupffer cells
greatly improved the elimination efficiency of PEGylated
AuNPs. Furthermore, ultra-small 4 nm AuNPs underwent
a more efficient hepatobiliary elimination than larger par-
ticles, because they were less efficiently captured by the
Kupffer cells and had a greater chance of moving from the
liver endothelium to the hepatocytes [58]. According to our
pharmacokinetic and biodistribution data and the above
studies, we could assume that the characteristics of our
AuNPs-PAA-Ctxb promote their rapid sequestration by the
Kupffer cells and splenic macrophages after IV administra-
tion. The clearance of the AuNPs-PAA-Ctxb by these cells
protects the organism from exposure to AuNPs-PAA-Ctxb
and their related metabolites. However, it also prevents
efficient nanoparticle elimination from the body, which
explains their long-term retention. Although the elimina-
tion pathways are not assessed in this research, signifi-
cant reduction of the gold concentration in the liver after
6 months could potentially result from occasional lysoso-
mal damage and macrophage cell death, induced by the
non-biodegradable AuNPs [59]. Subsequently, the hepato-
cytes could internalize some of the released AuNPs, thus
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leading to gradual and slow elimination via the hepatobil-
iary pathway [28, 56]. Renal elimination of AuNPs-PAA-
Ctxb is less likely, due to their size and negative surface
charge, as mentioned earlier. The localization of a small
amount of AuNPs-PAA-Ctxb in lungs and kidneys is less
clear, but resident alveolar and kidney macrophages could
be involved.
Since the AuNPs-PAA-Ctxb were rapidly removed from
the blood circulation and mainly sequestrated by the liver,
we were interested in the effects of AuNPs-PAA-Ctxb on
the liver. Therefore, we investigated the activity of the liver
enzymes ALT, ALP, AST and GGT in serum 6 h and 24 h
post-injection. GGT activity was undetectable in all serum
samples, and ALP activity was not significantly different
from the control groups. This suggests that there was no
obstruction of the biliary tract. However, AST and ALT
activities (characteristic for hepatocellular injury) were
significantly increased 6 h after AuNPs-PAA-Ctxb injec-
tion, compared to the 0.9% NaCl or AG control groups,
respectively. These increases were no longer detectable
after 24 h. Since the ALT and AST increases were min-
imal (1.5 and 2 times, respectively) we should question
whether the statistically significant differences were also
biologically and toxicologically relevant. In comparison,
a toxic dose of acetaminophen, which results in severe
liver injury, can increase the serum ALT and AST activi-
ties to several hundreds to thousands U/L in mice and rats,
4–12 h after administration. These activities can increase
further after 24 h [60, 61]. Therefore, if the AST and ALT
activity increases in our study were indeed biologically
relevant, then the AuNPs-PAA-Ctxb-induced stress to the
liver was only mild and transient. Several other studies
observed no significantly elevated liver enzyme activities
up to 90 days after AuNPs administration compared to the
controls [21–23, 25, 30, 49, 62–65]. Injection of 3% AG
did not significantly affect the enzyme activities compared
to the 0.9% NaCl controls, indicating that AG does not
lead to hepatic injury.
In our previous in vitro study, microvascular endothe-
lial cells were shown to be the most sensitive cells to
AuNPs-PAA-Ctxb, compared to human kidney and liver
cells. Therefore, we investigated the serum levels of spe-
cific cytokines related to vascular damage and inflamma-
tory activity. Out of all the cytokines that we investigated
(RANTES, IFN, IL-1, IL-2, IL-4, IL-6, IL-10, TNF,
GDF-15, ICAM-1, CCL2, CXCL-10, P-selectin, PCSK9,
uPAR), only the serum levels of GDF-15, P-selectin and
ICAM-1 significantly increased 6 h after AuNPs-PAA-
Ctxb administration, when compared to the 0.9% NaCl
and AG control groups. For GDF-15 and P-selectin,
the increases were transient and no longer detectable
after 24 h. The serum level of ICAM-1 remained ele-
vated after 24 h. It should be noted that ICAM-1 was
also near-significantly elevated 6 h after AG injection,
when compared to the 0.9% NaCl control group. Unlike
after AuNPs-PAA-Ctxb injection, ICAM-1 level was no
longer increased 24 h after AG injection. Therefore, we
could suggest that AG might transiently increase ICAM-1
expression, which could be enhanced and prolonged by
AuNPs-PAA-Ctxb. Finally, the chemokine RANTES was
significantly elevated 6 h after AG administration, com-
pared to the 0.9% NaCl control group. However, this
was not observed 6 h after AuNPs-PAA-Ctxb admin-
istration, which questions the biological relevance of
the increase or indicates that AuNPs-PAA-Ctxb elimi-
nated the effect of AG on RANTES expression. GDF-15,
P-selectin and ICAM-1 have been identified as biomark-
ers that reflect acute inflammation, endothelial cell acti-
vation and the recruitment of leukocytes to the vessel
wall [66]. However, the increases associated with these
markers in this study were slight and mostly transient.
Furthermore, levels of none of the other pro-inflammatory
cytokines were significantly elevated. Based on these find-
ings, we could propose that the risk of vascular damage
and any acute immune response elicited by our AuNPs-
PAA-Ctxb is limited. In the literature, different outcomes
on immunoreactivity after AuNPs administration were
identified. For example, liver mRNA levels of several
adhesion molecules (ICAM-1, E-selectin and VCAM-1),
chemokines (CCL-2, CCL-3, MIP-1 and RANTES) and
inflammatory cytokines (IL-1, IL-6, IL-10, IL-12 and
TNF) were transiently elevated 30 min to 24 h after
administration of AuNPs, which suggests the presence
of an acute immune response [15, 67]. In contrast, var-
ious other studies observed no significant differences in
hematological white blood cell indices and TNF-, IL-1,
IL-6 and IL-10 levels after AuNPs administration [21–
23, 30, 49, 63–65, 68]. Interestingly, a study focusing
on the effects of antibody-conjugated AuNPs on the vas-
cular system found that IV injection of AuNP-IgG even
suppressed leukocyte adhesion to vessel walls. Further-
more, AuNPs-IgG prevented the expression of adhesion
molecule PECAM-1, chemotaxis and oxidative stress acti-
vation on neutrophils after stimulation, which suggests an
anti-inflammatory effect [69].
Finally, since the AuNPs-PAA-Ctxb had a slow
excretion rate from the body, we performed histological
examinations at 1 week, 4 weeks and 6 months after
injection. We did not observe any signs of toxicity until
4 weeks post-injection. Consistent with our results, other
studies showed normal organ morphology without apop-
tosis, necrosis and fibrosis until 90 days after AuNPs
administration [21–23, 25, 30, 49, 55, 64]. However, at
6 months post-injection, we were able to observe a slightly
increased presence of (1) immune cell infiltrations in the
lung, (2) apoptotic lesions in the germinal center and
white pulp of the spleen, and (3) casts in the collecting
tubules of the kidney. Importantly, apoptotic lesions in
the germinal center of the spleen and casts in the kidney
were also occasionally observed in the control group, but
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from the qualitative images obtained, they seemed to be
more noticeable 6 months after AuNPs-PAA-Ctxb injec-
tion. Comparable histological observations of the spleen
and kidneys were reported previously. However, these
results were obtained 1 week after injection [70]. The ori-
gin of the kidney casts in our study are unclear. In the
spleen, the apoptotic lesions were mostly characterized
by the presence of tangible body macrophages (TBMs),
which are responsible for the clearance of apoptotic lym-
phocytes and required to down-regulate the germinal cen-
ter reaction. This could suggest a potential activity of the
adaptive immune response [71]. Interestingly, although a
major proportion of the AuNPs-PAA-Ctxb accumulated in
the liver, no histological abnormalities were observed until
6 months post-injection, which suggests organ-specific
sensitivity to AuNPs-PAA-Ctxb. This is not consistent with
another study, which shows increased apoptosis in the liver
1 week after IV injection of 4.26 mg/kg 13 nm PEG-coated
AuNPs [15].
Overall, from our functional and morphological obser-
vations, and since all the mice survived, showing normal
behavior and appearance over the course of the experi-
ment, we consider the toxicity of our AuNPs-PAA-Ctxb
to be reasonably low. These results could be related to
the surface charge and administration mode, which can
affect the toxicity profile of the AuNPs. In fact, a study
by Zhang et al. demonstrated that intravenous injection of
13.5 nm AuNPs showed the lowest toxicity compared to
the intraperitoneal and oral administration routes, which
caused a significant decrease in body weight, spleen index
and hematocrit [72]. Furthermore, in general, positively
charged AuNPs exhibit a higher cytotoxicity profile than
their negatively charged counterparts. Usually, this dif-
ference is associated with the electrostatic attraction and
adhesion of the positively charged AuNPs to the nega-
tively charged cell membrane, causing depolarization of
the plasma membrane and disruption of the membrane
integrity [73, 74]. Wang et al. confirmed that the AuNP
surface charge influences the toxicity in healthy mice, with
3 mM of positively charged gold nanoclusters (3.7 nm)
inducing the most prominent effects on the peripheral
blood system, compared to neutral and negatively charged
gold nanoclusters [25]. Similarly, in zebrafish embryos,
positively charged AuNPs (0.8–1.5–15 nm) were lethal at
exposure concentrations higher than 400 ppb, whereas the
negatively charged AuNPs induced sub-lethal toxic effects.
Neutral AuNPs caused no adverse biological response up
to a concentration of 50 ppm [75]. Nevertheless, we are not
able to exclude long-term toxicity of AuNPs-PAA-Ctxb
with certainty. Therefore, we recommend future research,
which focuses on in vivo AuNPs toxicity, to consider long-
term measurements beyond 6 months, including exper-
iments assessing kidney functionality, liver functionality
and immunoreactivity. Furthermore, this study was per-
formed after a single IV injection. In a clinical setting,
the use of AuNPs as radiosensitizing agents may require
multiple injections. In fact, multiple intravenous injec-
tions resulted in a cumulative increase in AuNPs con-
centration at the tumor site in Swiss nude mice [76]. It
should be noted that multiple dosing did not cause adverse
effects in normal tissue, as demonstrated by several other
studies [49, 70, 77].
CONCLUSIONS
In conclusion, this study describes the pharmacokinet-
ics, biodistribution and toxicity of our in-house produced
AuNPs-PAA-Ctxb after a single IV injection. We demon-
strated that the acute toxicity of AuNPs-PAA-Ctxb on
the liver and vasculature, tested as increased serum AST
and ALT activities, and elevated serum levels of GDF-
15, P-selectin, ICAM-1 and RANTES, was limited and
transient. However, the rapid clearance of the AuNPs-
PAA-Ctxb from the blood, sequestration by the liver and
spleen and long-term retention of the AuNPs-PAA-Ctxb
in these organs could be limiting factors for the use of
AuNPs-PAA-Ctxb as radiosensitizing agents in vivo. In
order to evaluate the radiosensitizing potential of AuNPs-
PAA-Ctxb, we are currently labeling the nanoparticles with
177Lu, which allows real-time assessment of the nanoparti-
cle distribution and elimination in tumor-bearing animals.
Since splenic apoptosis, kidney casts and immune cell
infiltration in the lungs appeared to be more noticeable
at 6 months post-injection compared to the controls, we
could not exclude long-term toxicity with certainty. There-
fore, we recommend that future in vivo studies consider
long-term toxicity and the elimination of AuNPs after mul-
tiple dosing, in their preclinical validation as new targeted
anti-cancer therapies.
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